GCP
CADX

GSA Capital Partners’s CADENCE PHARMACEUTICALS, INC COM STK CADX Stock Holding History

GSA Capital Partners’s Portfolio CADX Stock Details CADX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-23,393
Closed -$212K – 2019
2013
Q4 		$212K Buy
+23,393
New +$169K 0.02% 1436

Other funds holding CADX

OP
Omni Partners London, United Kingdom $2.03B AUM 126.33% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

GSA Capital Partners's CADX Position: Q1 2014 in Review

GSA Capital Partners sold out of CADENCE PHARMACEUTICALS, INC COM STK (CADX) in Q1 2014, closing a stake of 23,393 shares — an estimated $212K sold.

GSA Capital Partners first reported a position in CADX in Q4 2013 and held it in 1 quarter. The position peaked at $212K in Q4 2013. 3 funds tracked by Wall St. Rank hold CADX as of Q1 2014.

  • GSA Capital Partners reported no remaining CADENCE PHARMACEUTICALS, INC COM STK position as of Q1 2014 after selling out during the quarter.
  • GSA Capital Partners sold 23,393 CADENCE PHARMACEUTICALS, INC COM STK shares in Q1 2014, an estimated $212K.
  • GSA Capital Partners first reported a position in CADENCE PHARMACEUTICALS, INC COM STK in Q4 2013 and held it in 1 quarter.
  • GSA Capital Partners's CADENCE PHARMACEUTICALS, INC COM STK position peaked at $212K in Q4 2013.
  • 3 funds tracked by Wall St. Rank held CADENCE PHARMACEUTICALS, INC COM STK as of Q1 2014.

Based on GSA Capital Partners's 13F filing for Q1 2014, filed 14 May 2014.